Alrighty. Good afternoon, everyone. Day one of our Jefferies London Healthcare Conference. It really has been a joy to see all the clients and all the companies. My name's Akash Tewari. I lead our pharma and biotech research efforts here at the firm. I have the pleasure of hosting Latigo, not Latigo. I've made this mistake. Todd and Neha, it's really great to host you. Todd, why don't I hand it off to you for some intro remarks, and we'll get started.
Awesome. Thanks, Akash. Hey, good afternoon, everybody, as well. Thanks for being here. Excited to be here. I've been in my job about two weeks. I come with a background deep in commercial, probably 30-plus years in the industry, the majority of that around pain, over 15 pain drugs that I've either launched or managed. I got a number of products approved, built a number of companies. A lot of commercialization deep as we think about the next step for Latigo. We've done a tremendous job with clinical progression. The IPO was a phenomenal success. Now the next step is really building out the commercial team to match the current team we have and prepare with the data that we are initially seeing that looks differentiated and really gives us kind of optimism on what we could do in the marketplace.
The earlier we get involved, the more we can start to influence particularly the payers, maybe the medical side and policy. That gives us a lot of opportunity to kind of highlight and discuss our differentiation to get improvement in that. We're pretty excited about where Latigo is. We obviously have the abdominoplasty study has been completed, published in the New England Journal of Medicine. Next study will be our bunionectomy. We also have a safety study, which we're guiding to be read out second half of next year. We also have in the chronic OA, we have LTG-321, which is in process with its phase II proof of concept study that we also guide to read out second half of 2027. We have obviously further work being done.
LTG-418 is a little bit deeper in our pipeline, but it's a next generation, we like to think of it, NaV1.8, that we can optimize and then further work in our discovery group, not only on NaV1.8 optimization, but kind of further targets that we're looking at. A lot of great progress, but also a lot of excitement for what we can do with both onzotrigine when it eventually will get approved, and then also the rest of the pipeline, which I think when you look at it, we're probably the broadest and deepest pipeline as we build out that best-in-class innovative pain company that we're working on.
Understood. Todd, I am going to ask you the question you probably get in every single one of these meetings, which is, it is not typical to have a management change, and I think we all have a lot of respect for Nima. Why now? From a board perspective, why did the change make sense at this time point? You have a ton of experience when you think about pain launches and commercial launches. When you are really building out a market like NaV1.8, I mean, A, how do you see the market fundamentally differently than Vertex, and why do you need to start doing some of that work now?
Yeah. No, fair. Probably three questions in there. Probably just first, and we have answered this, and the good news is I think everybody sees, even though the transition from Nima to myself may be a little bit abrupt, but very smooth, right? I think I have the deep pain experience and commercialization, which is that next phase we are moving into. Fortunate enough to have Nima, who built out a great team, led the team through the outsized IPO. He is able to stay on as an advisor through 2027. So, a lot of continuity. We have a great team in place. There will be no changes. I have been fortunate enough to be able to work with a team that, from top to bottom, seems to be top in the game, which is great.
What you will see us maybe adding a few people in the commercial space, some commercial leadership will be coming in soon. Really just opportunistic. I sold a company, Corium, which was in the ADHD space, to Collegium. That wrapped up really at the end of the summer, as I was looking at a number of other things and as we are looking at Latigo really moving into this commercial space. If I took something else, I would be out of circulation for three to five years. So, a little bit opportunistically, the board decided let us make the move then now to commercialization, which really leads to the next question, which is when should we be doing something? Really today, right? We have really good data that has been published. First of all, unique that it got published.
I think also the differentiation that it showed in onset, with 52 minutes versus Journavx , 119 minutes, two and a half times faster. As all of us know in the marketplace, the behavior is shifted for no other reason than onset, right? Doctors need to know that it is going to work fast, work for patients. On a lot of levels, that is important to them. It is really, for the majority of doctors, unless you are an academic, it is really the only thing that is going to matter to them.
With that puts us in a position where today, and we have already even in the last couple weeks have had a number of advisory meetings that we are working on, to really start forming how do we position ourselves because of the differentiation we have, because of how large the market is, and as you look at Journavx and what it has done, right? I think it is a tale of two cities.
A lot of people would say, "Hey, it is early launch. It was not really that great." What it has ended up in is really validating this NaV1.8, that the market is hungry for an alternative to opioids or even NSAIDs. Its latest data that it shared two weeks ago showed over 2 million scripts run rate in both NRx and TRx, and a 50% growth in its volume quarter-over-quarter. That is two years in the launch.
That is actually pretty significant. I think as you think about when we might come on the market for onzotrigine, that is going to be well past 2 million scripts. That could be 2.5, three times. No one is guiding to anything, but you can imagine how big that will be. When we look at then launching into a marketplace, a second to market, we get to learn a lot. Where we are going to be able to step into is when we can come to market, talk to doctors about a 53-minute onset versus 119 minutes. When you think about why they want to move away from the opioids and NSAIDs, what they really want is something safer, they want something cleaner. Though Journavx is relatively clean compared to those, it does have drug-drug interactions. We are not seeing those in our preclinical or even in the current data.
Now we can walk in and tell a doctor that has already adopted 1.8 as an acute pain drug. Doctor, we have a more efficacious product, and we are a little bit cleaner, so why not move your business to that? On top of that, there are doctors sitting on the sidelines right now that really want something different, but they do not feel like they are getting the efficacy out of it. We can now pull in and really expand the market to that point. So we have a nice chance to kind of cannibalize what is out there, which is a great fast start for anybody. Secondly, we can expand the market. The second piece to how we have to look at it and why we need to start today is really it is the economics around it, right? It is the gross-to-net.
Everybody now knows the number one strategic lever in commercialization is gross-to-net. It is the profitability per script. When you look at what Journavx did, in this last quarter, they ended up at about a 76%-78% gross-to-net. That is an anomaly, right? They had a transfer from one of their government contracts. What they are going to settle into is about 50%-60%. I got to be honest, I think if most of us want to look, novel first to market differentiated products, that is a high mark. I think that speaks to their efficacy, right? Also the label that they really came to market with.
We're going to get to come with not only the efficacy we talked about, we're also working, as you think about the two studies we have, both with opioid sparing as we looked at the rescue data. Then we're adding the Vicodin arm that we had in the abdominoplasty, and we're adding Percocet to the bunionectomy arm. That just gives us a fullness of label that as we start now interacting with the payers, we can start and really influencing the clinical and the policy kind of decision makers. If you don't do that now and you wait till six, nine months before launch, you're really just in that economic game, whereas now we have a chance to start to influence that. The other big piece we have is that policy's evolving.
Right now, we know the NOPAIN Act really has an impact in the hospital. Because of that, we're going to get differential benefit from that. We also, because we have differentiation, we can get more aggressive in how we expand that. Then I think finally, just when you look at the programs, because we're second to market, we're not going to have to deal with all the patient support programs that they had to. Because we have differential efficacy, we're not going to have to keep them up. When you do that really gives you kind of now this profitability of script that we can look at being differentiated, but it also looks at the volume, could be really exciting for what we launch into.
That's very helpful. I just want to put a finer point on that. Vertex absolutely has talked about long-term gross-to-net being that kind of 50%-60% range, which to be fair, I mean, it's pain, it's an in-hospital launch in some instances. That is not unusual. What you're saying, I think it's one of the first times I've heard your team say this. To be clear, if Vertex is saying gross-to-net is 50%-60%, what's your sense if you can get opioid sparing on the label, if you have a faster onset of effect? Are you saying you might have a material benefit on long-term gross-to-net versus what we see with Journavx?
Yeah, I mean, this is the key strategic question, right? At the end of the day, gross-to-net's a multitude of different factors and levers that you got to pull. One of the things that we're looking at is Journavx looks like 50% of their scripts are coming out of the hospital.
I do not know the breakdown specifically, but inherently, the hospital is going to be a lot less profitable script. If they have 50% coming out of there, it is because they are calling on who they are, the surgeons, the orthopedic surgeons, and they are getting used because of the NOPAIN Act. When you look at scripts outside, you get a little bit more value because it is more commercial scripts. It is actually a less constrained economic point. What we are going to do is we are going to have to offset what they worked on in the contracting that they established with the payers. Part of that is nuance in how you do that and tools in how you do that. What it looks like they did was kind of peanut buttered their contracts.
If you really look, there is some nuance, and I am not going to guide to anything, but when you really break down these contracts, there are different formularies, and you can contract for specific formularies, which means you are not paying for business you might already get, so you are double-dipping, you end up getting a profitability impact. The other thing is really when you start looking at the patient support programs and copay, that is the other big lever, and we just are not going to have to do the same level of patient support because, A, they have defined the market, B, we have more efficacy, and so you are not having to pull that through constantly with a doctor who needs to feel comfortable that they are going to get someone started fast when we can get it.
Then three, the gross-to-net impact from copay is where you see a lot of variation quarter to quarter, and the tool sets and maybe the creativity in which we can be, because we will have a lot of targeting data, we will have a lot of insight into the value per doctor, and where do you direct your sales force, and where are you going to see the impact of copay and how expensive that gets. We are going to have a lot of that opportunity through analytics to determine where we go. I think we have a good chance of really optimizing gross-to-net. I will not guide to anything we are going to do yet, but we definitely are going to be able to optimize off what they have done.
That is very interesting. By the way, I will note, for as many investors who think pain is, Vertex does not talk about it, the scripts speak for themselves, and you notice Merck actually just put a NaV1.8 into the clinic. Clearly, a lot of pharma's still think this is a very important market. I do want to hit on, okay, there is this provocative question, which is, why would I give an opioid in an acute setting at all if I can kind of avoid it? But there is this element of like, okay, maybe I need a little more efficacy, maybe I need a faster onset of effect. I think some of the KOL work our team has done is that maybe the switch with just Journavx alone could be 40%-50%. It is very significant.
But in order to really drive that 80%, 90%, there are other attributes that might be needed. I want you to define it, right? So like if you were to define a differentiated NaV1.8, when you think about SPID, when you think about onset of effect, when you think about maybe DDIs, like for investors so we can all call your shot, what do you think this profile will be in phase III, and what should we expect?
Yeah. I'll give you my thoughts, and then obviously jump in with anything you want to add. So, I think when you look at it's kind of, to your point, right, KOLs are looking at pain relief. They measure behavior changes because of onset. But what they'll look at first, right, is you get the SPID48 score and the differential. Obviously, approvabilities against placebo. We showed 62 score for abdominoplasty. Next question is, what are we going to see in bunionectomy, right? And that starts to become the question. And what we feel like is good is that onset's going to carry over, right? It doesn't seem like that's going to be a concern. I think secondly, even if you saw a fall-off of what Journavx saw, right, that same differential, we still stay in the 40s, which is comparable to Vicodin.
We're staying in a comparability to it. Now, we've powered the study, so if we drop as far down as Journavx did, we still have an approvable drug. So we feel really good about how that data's been set. I think secondly to your question, the 53 minutes is significant. There's just no two ways about it. But then the drug-drug interaction profile, the fact that we can now come out and say, at least so far in clinical data, very, very, very clean side effects, and we have this efficacy, that's where the difference goes. Because when you start talking to the payers and you start talking to doctors and hospitals, that efficacy is probably not the reason they're going to give us a better situation.
It's when you look at the comparability of the side effects and you start being able to do HEOR or economic impact studies against things like opioid-induced constipation, which need to be treated by a prescription drug. You can't get over-the-counter relief for opioid-induced constipation. So that's more product. When you start looking at economic impact of hospital revisits, you're getting the efficacy, so you're not giving that up. So, they're not adding extra products because they got to get main They're just going because they're either using opioid or our NaV1.8. Now you have that economic impact. And then when you think about discharging from the hospital, right, it's all about mobility. Well, if you can use a NaV1.8 versus an opioid, now you can get discharged faster and maybe more consistently. All those start to be a reason you'll get really economic shifts that will happen.
Doctors are going to want to know, "Do I just get pain relief faster, and is it safe, and is it cleaner?" That is the profile I think happens. The only thing I will add really quickly is when I look at the competitors coming out, because we do know Merck, Grünenthal, Lilly, a lot of people are looking at it. It is a massive market, so it is 250 million scripts, it is 80 million patients. There is a lot for a lot of market share there, right? But I do not know how you position against a drug if our profile continues, that it is 53-minute onset and no drug-drug interactions, and really kind of a very, very clean side effect.
For us, I feel really good about what we can launch into, but I also feel very good about how we protect ourselves if anybody else comes to market from that standpoint. Anything else you would add?
The only thing I would add is on the opioid-free endpoint-
Yeah, great point.
which is something that Journavx doesn't have today. We utilize opioid as a rescue in abdominoplasty, plan to do the same in bunionectomy. That allows us or enables us to get opioid-free data in the label. That's another data point from an HEOR payer perspective to demonstrate, right, that prescribing our drug does not mean you need to prescribe an opioid on top of that. In abdominoplasty, we showed that 52% of patients did not need an opioid.
That's an easy sort of math calculation you can do in terms of avoidance of prescribing a drug.
We'll most likely have that in our label.
Yeah
Which Journavx doesn't, so.
Right. I want to hit on a nuanced point, but it's an important one. There's an investor perception, DRG, if I'm a doc, and as a bundled payment, why would I not just give a generic drug if I'm going to get paid a fixed amount? I'm eating into my own cost basis. I do think that kind of ignores some of the real-world data we're seeing and the fact that DRG is not just at that acute event, but it's really going out to a month, right? If you have side effects later. This is quite important. Is your team confident that there is an economic argument in a DRG setting, in an acute setting, for a doctor to give a branded drug like yours and not a regular opioid?
Yeah, no, it's actually a great question. It's an interesting question because, like, when you think about DRG, there's so many different elements to it, right? One is the cost of an opioid or even an NSAID is pennies. Our cost, most likely, if we're in range or even slightly, it's not going to be that much when you think about the total DRG for surgery. Put that aside, because it definitely is a couple hundred dollars difference in profit. The next piece is, don't forget, the biggest metric for hospitals now is this Triple Aim, right? It's not only the efficacy, it's the outcome of the patient. It's also doctor being able. It's also patient satisfaction, right? That's how they get their bigger reimbursement when they think about Medicare payments.
When you think about Triple Aim and you can come in and say, "Hey, we have a cleaner, safer, less." You're not getting CNS, you're not getting nausea, you're not getting that. There's a lot of benefit to that when you think about more holistic reimbursement for a hospital as well. I think that's a piece we don't talk enough about that comes with that benefit. I think also, this is where cost of care versus cost of pill comes into play.
I think anymore, the sophistication, when you look at systems, you look at individual hospitals, you not only have your head of pharmacy, but your CFOs are getting more involved because what they don't want to do, and this is back even in the 90s when you sold once-a-day antibiotics versus multi, head of pharmacy would say, "Well, gosh, that cost is more because I'm buying." What they didn't go look at is nursing time. They didn't go look at the cost of the tubes, the injection. We're going to have a really powerful opportunity to talk about cost of care, especially because even though the economics won't be that dramatic compared to what they could be, the impact we could have on the broader cost is real. I think we have a really opportunity to do that. That's the hospital.
The only other thing I would say, and this is kind of something we're going to investigate a lot in the next year, is when we launch this product, I don't know if we want 50% of our scripts to come out of the hospital, right? I mean-
Right
There's so much opportunity when you look at net profitability per script. We definitely want to be in the hospital space because I think we have it there, but we also think there's a lot of other targets that you could expand past that I think Journavx has just stayed very specific because that's the model of how they know to do it. But when you start looking at segmentation, you look at targeting, you also can target away from unprofitable or unproductive as well.
Understood.
I wanted to answer your question.
No, no, that's quite helpful.
Is important.
Now, on two points. The way our team kind of looks at it, we'll see if the drug is differentiated head-to-head, and we'll get the data. There is something, you talked to Neil, and he knows how to run clinical trials. There is something about the Vertex bunionectomy study that might have been an outlier to historical pain studies, right? Whether it's number of sites, whether it's on nerve block, whether it's on site selection itself. Can you talk about what you plan to do in terms of trial conduct for your bunionectomy trial? Let's assume the drugs are the same. I know, you won't agree with that.
Yeah, I know where you're going.
But in terms of just
Let's start with-
pure trial conduct, what should investors be paying attention to that gives you a leg up?
Yeah, that's a great question. Neha, why don't you go ahead and answer that one?
Yeah, so I'll start. I think one thing that's important to note that Vertex, when they designed their phase III, both abdominoplasty and bunionectomy trials, they were powering the studies to be a show non-inferiority to the opioid comparator, which was Vicodin in that case. They ended up running much larger studies, so 1,000-ish patients, and that required them to go to multiple sites, so 20-plus sites. In pain, what Neil would say, is when you start increasing your site footprint, you introduce variability, and having sort of a tighter network of sites and controlled, it matters a lot in pain, given it's a subjectivity involved.
For our bunion study, first of all, we're powering versus placebo, and it's a 480-patient trial that we're running, and we are able to stay within sort of a six- to eight-site footprint, and all these sites are ones that have experience with bunionectomy, and we look at sort of placebo response and what have they shown, have they had successful trials in order to select those sites? Those are really important as part of it. The other piece that, for us, that's different, is the nerve block that you talked about. One of the things that was hypothesized with Journavx in terms of why it had a four-hour onset in bunionectomy, it had a two-hour onset in abdominoplasty, was that there was potentially interference from the nerve block that was used as part of the procedure in bunionectomy.
It's common to use a nerve block in bunionectomy surgery, and that nerve block is typically a pan-Nav. Could that have introduced a variable in there that led to longer onset? Again, we don't know if that's true or not, but in order to prevent any sort of, to mitigate on that, what we're doing is pulling the nerve block five hours before randomization, versus Vertex was much closer to the time of randomization, to allow for that interference to potentially wear off before patients are randomized. Those are just a couple
Right
examples of things that we're doing to mitigate.
Understood. Let's hone in a bit on the addition of the Percocet arm. Again, that was also a little surprising. A, when you had your pivotal abdo data, can you talk about what the FDA had kind of suggested, what did the draft guidance suggest about including another opioid in the bunionectomy study? Number two, why you were in a capital position to actually make a change? Then number three, and this is where I do think it gets a little tricky, you're not taking the highest dose of Percocet, but there is this kind of question of, well, how do we compare this relative to Vicodin? Because everyone will look at that with the abdo data you put. Expectation set that as well for us.
Yeah, I think, Neha, jump in when you.
Yeah
When you feel like you're going to. I think a couple of things, and I think it's a great question, right? Because first of all, we got to think about just fundamentally what are we trying to do? We're trying to get a product approved, right? So, we're going to work against placebo, SPID48 separation in both trials. Then what we want to get is we want to start to get the opioid sparing, which is from the guidance of the FDA, which is this rescue component to it. So, we have really three parts of these studies. The separation between placebo for approval, the rescue component of using an opioid for that, and we showed 52% rescue in the abdominoplasty. That shows majority of patients. So that gives us language that starts to talk about opioid sparing.
The second piece is the comparability to Vicodin, and abdominoplasty is the most commonly prescribed product. We show comparability. We actually showed better data, both efficacy, onset, and what we now have is not only that comparability, but more importantly, we have the side effect profile that now we can put in our label because of that. As we talked about earlier in the commercial, it's that side effect profile that highlights the reason economically a policy payer or hospital is going to make a different decision. So that becomes that opportunity. Now you come to the second study and you say, "Great, what are you doing adding Percocet then?" Right?
I think first of all, we did all the work and we've done the research and looked and it said, most of the clinical studies will show you in bunionectomy, both Percocet and Vicodin will work relatively similarly. So, when we think about kind of the opportunity to be successful, that's a great outcome. Doctors and the CDC would list it as a more potent drug, 1.5 times more potent than Vicodin. For us, then we get the comparability again, same thing, placebo, rescue, but now back to we're using Percocet because we had the upside IPO. We didn't have the capital beforehand. Neha obviously doing a great job in the IPO, gave us more money, and we could all look at it and say, "Let's keep adding," because the guidance from the FDA is have the opioid sparing from kind of the saving of it.
But then the second part is the more data you can add, then the more robust it becomes a different negotiation, becomes a different discussion. Now again, we have a second set of data with the number two most prescribed opioid where we can show comparability. Even if we show a little less than that, we are still a product that is viewed as very potent, but we also do not compromise the great data we already have. We get a new set of data, and more important again than efficacy in this data is going to be the side effect profile comparison, because it is that that then has it. Now what we get to have is approved drug, whatever that label comes with it. We get some of the opioid sparing from the safety part of the data where we saving with the opioid.
Or third, we get now this label that has comparability side effect-wise, that now lets us promote with that, because it is in the label under the clinical trial section. It allows us to do HEOR studies, allows us to also potentially work with the economic impact. So, that becomes the idea for Percocet, and that becomes kind of the idea of adding it on once we had the additional capital to do it.
Yeah. We were able to maintain timelines, right?
Great point.
Right.
We got site footprint at six to eight, so not compromising sort of what we'd want to achieve in terms of
Not power to show benefit against
We're not powering against
Stay powered to placebo, not that.
Right. I am going to stick in one more question on LTG-321. I think there is a lot of people are like, "Well, look, we know these drugs don't work in chronic pain." Then you are like, "Well, there is VX-150. It was an IV, and it did show a clear signal." I do think there is a bit of level setting on expectations there that I think would be helpful. So, two-part question here. One, how confident are you that you can deliver a PK/PD profile like VX-150, which was an IV drug? It is not easy to do necessarily in an oral formulation. Then number two, your confidence that the signal we saw with VX-150 is, quote unquote, "real," and you can see a role for this MOA in chronic pain.
Yes. I will start, and then, Neha, why don't you finish up? I think we are excited about it for a couple reasons. One is it is a bigger market. Secondly, when you look at LTG-321 and NaV1.8s, they are purpose-built for musculoskeletal pain. We saw LTG-321, all the preclinical, both the target site inhibition was at 95%, which is. Then in the cold pressor and some of the other clinical, was the most potent we had seen of any of the NaV1.8s. So, we feel really confident putting that forward, and obviously in the study. Also, that it is a QD drug. When you think about chronic versus acute, there is a lot of benefit to that. That is the reason on a profile basis we are really confident about moving forward with it.
We think that then the study work and some of the other things we are doing are the right studies to kind of prove that out. I don't know if you want to add anything.
Yeah. So, maybe on VX-150 in particular.
Yeah.
Correct. We are modeling our proof of concept trial off of that positive study that was run. We have also run multiple NaV1.8s in cold pressor, and we do rely on cold pressor as a biomarker for us in terms of translating the pain signal into humans and then into efficacy studies. VX-150 also had a positive acute pain study, so they did run a bunion study. It was a positive study. Mechanistically, there is a role of rationale to believe that NaV1.8s are, again, better suited for musculoskeletal pain versus neuropathic pain, right? If you think of even opioids are used in musculoskeletal pain, are effective in musculoskeletal pain, not neuropathic pain. Opioids have also been run in cold pressor studies and have shown to have efficacy in that setting.
We kind of look at that model as our reason to believe that it will translate and is a biomarker that we think even we have put suzetrigine in it and have shown through that efficacy differential has translated into abdominoplasty. You can take two leaps of faith. One is acute pain is musculoskeletal pain. That should translate into OA. You have the clinical sort of data from VX-150 that has also been shown in both models. The last thing I would throw in there is our preclinical data, which I know we have running out of time to talk about, but we have shown that NaV1.8, again, is better suited as a monotherapy to block propagation of pain versus, which is really-
Something like DPN.
Yeah, which is less like DPN, right?
We will get you out of here, but I really do appreciate the time. Thanks so much, everyone.
Yeah, thanks, Akash. Thanks, everybody.